Senti Biosciences is a Series A next-generation biotechnology company that designs gene circuits and programs cells for tremendous therapeutic value. Senti's mission is to engineer an entirely new class of medicine that will transform people’s lives by curing the most complex diseases. Backed by a syndicate of leading biotech and tech investors including NEA, 8VC, Lux, Pear, Menlo Ventures, and Amgen Ventures, and led by an experienced team with deep translational knowledge of advanced cell therapies, the company is leveraging its proprietary gene circuit repertoire to solve the most pressing unmet needs in oncology and other difficult disease areas.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Allogeneic gene-modified cell therapy stimulating local anticancer immunity in advanced solid tumors
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):